Skip to main content
. 2022 Sep 5;12:989167. doi: 10.3389/fonc.2022.989167

Figure 3.

Figure 3

IVM reshaped the tumor immune microenvironment in lung of melanoma mouse model. (A) FACS analysis of monocytes (CD11b+Ly6C+), neutrophils (CD11b+Ly6G+), CD4+ T cells (CD4+) and CD8+ T cells (CD8+) in lung of tissue from control, B16F10 or B16F10 with IVM treatment group mouse at day 21 after melanoma inoculation. (B, C) Frequency and cell number analysis of Polymorphonuclear (PMN) neutrophils, monocytes (Mo), CD4+ T cells and CD8+ T cells from mouse in (A). (D) FACS analysis of neutrophils (CD11b+Ly6G+) in bone marrow (up), peripheral blood (middle), spleen (bottom) from control, B16F10 or B16F10 with IVM treatment group mouse. (E–G) Cell percentage analysis of neutrophils of the bone marrow (E), peripheral blood (F), spleen (G) from mouse in (D). Data in all panels are representative of at least three [(A–G), n = 3, mean ± SD] independent experiments. *P < 0.05; ***P < 0.001; ns, no significance [two-way ANOVA in (B, C); one-way ANOVA in (E–G)].